175 ADJUVANT, PVAX14 DNA, AS AN IMMUNOTHERAPY FOR A MOUSE MODEL OF HIGH RISK MYELODYSPLASTIC SYNDROME (HR-MDS) EXTENDS SURVIVAL AS ADD-ON TREATMENT TO AZACITIDINE (AZA)